Close

Teva to Present at the Wells Fargo 2016 Healthcare Conference

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Pharmacy’s Impact on Reducing Medication Errors in Hospital Settings

Medication errors are a big problem in healthcare because...

How to Dispose of Pharmaceutical Waste

Proper pharmaceutical waste disposal is crucial for protecting our...

Semaglutide 101: What You Need to Know About This Game-Changing Medication

In the realm of modern medicine, breakthroughs are not...

Health Benefits of Pre-work Supplements

Whether you are a workout expert or just starting...

Teva Pharmaceutical Industries Ltd will host a live audio webcast at the Wells Fargo Healthcare Conference. Eyal Desheh will present on Wednesday, September 7, 2016 at 1:10 PM ET.

What: Teva Presentation at the Wells Fargo 2016 Healthcare Conference

Who: Eyal Desheh, Group EVP & CFO

Teva Pharmaceutical Industries Ltd.

When:Wednesday, September 7, 2016

Where: www.ir.tevapharm.com

About Teva
Teva Pharmaceutical Industries Ltd is a leading global pharmaceutical company that delivers high-quality, patient-centric healthcare solutions used by millions of patients every day. Headquartered in Israel, Teva is the world’s largest generic medicines producer, leveraging its portfolio of more than 1,800 molecules to produce a wide range of generic products in nearly every therapeutic area. In specialty medicines, Teva has a world-leading position in innovative treatments for disorders of the central nervous system, including pain, as well as a strong portfolio of respiratory products. Teva integrates its generics and specialty capabilities in its global research and development division to create new ways of addressing unmet patient needs by combining drug development capabilities with devices, services and technologies. Teva’s net revenues in 2015 amounted to $19.7 billion. For more information, visit www.tevapharm.com

Teva Pharmaceutical Industries Ltd.

IR Contacts:
United States
Kevin C. Mannix, (215) 591-8912

or

Ran Meir, (215) 591-3033
or

Israel
Tomer Amitai, 972 (3) 926-7656

or

PR Contacts:
Israel
Iris Beck Codner, 972 (3) 926-7246

or

United States
Denise Bradley, (215) 591-8974

 

Latest stories